FindTrial
Sign In

A single-arm, multicenter, prospective clinical study on the treatment of locally advanced nasopharyngeal carcinoma with Adebrelimab combined with induction chemotherapy

A single-arm, multicenter, prospective clinical study on the treatment of locally advanced nasopharyngeal carcinoma with Adebrelimab combined with induction chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122114
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

Experimental group:Adebralimab combined with induction therapy

Sponsors

The First Hospital Of Nanping
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.18 years old = 6 months; 5.at least 1 measurable lesion (RECIST v1.1); 6. Participants voluntarily joined this study, had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Severe dysfunction of major organs such as the liver, kidneys, heart, lungs, or brain; 3. Active infections, immunodeficiency, or the need for long-term immunosuppressive therapy; 4. History of other malignant tumors or prior treatment with targeted therapy and other PD-1/PD-L1 inhibitors; 5. Major surgery within the past 6 weeks, allergy to the investigational drug's components, or contraindications.

Design outcomes

Primary

MeasureTime frame
Image complete remission rate;—

Secondary

MeasureTime frame
Objective remission rate;—

Countries

China

Contacts

Public ContactWu Shizhen

The First Hospital Of Nanping

272719457@qq.com+86 599 8605951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026